Recently, the results of the secondary analysis of VITAL research data were published in JAMA Network Open, a subsidiary of the Journal of the American Medical Association. Data shows that taking vitamin D is associated with a lower overall risk of developing advanced (metastatic or fatal) cancer, and weight can affect the association between them.
UTSpeaks: A medicated nation
Has Australia lost its way in a pharmaceutical love affair?
Professor Charlie Benrimoj and Associate Professor Mary Bebawy from the University of Technology, Sydney present at this public lecture on prescription medication held on 13 September, 2011.
How many pills will you take today? Do you really need them? What good (and bad) will they do you?
For many of us prescription medications mean the difference between good and ill-health. There’s no denying their important place in fostering well-being for many. But is it time to reflect on the complex forces at work when managing disease and medications and how this impacts you the consumer?
Featuring leading UTS researchers in pharmacy and using example case studies, this public lecture takes a critical look at how medications are prescribed and consumed in Australia. It considers whether we are getting value for money, the ideal health outcomes we hope for and whether new approaches to the responsible use and explanation of medications could be adopted.
Speakers:
Professor Shalom (Charlie) Benrimoj
Charlie Benrimoj is head of the newly-created UTS School of Pharmacy. Formerly he was Foundation Professor of Pharmacy Practice then Dean of the Faculty of Pharmacy and then Pro-Vice Chancellor (Strategic Planning) at the University of Sydney. He is a visiting professor at the University of Granada with research interests in the future of community pharmacy. He is widely published - co-authoring Community Pharmacy: Strategic Change Management in 2007. He was Australian Pharmacist of the Year in 2000 and received the Andre Bedat award in 2010 from the International Pharmacy Federation.
Associate Professor Mary Bebawy
Mary Bebawy has spent more than 14 years in research and teaching positions in academia and two years in industry as a post doctoral preclinical drug development scientist with Johnson and Johnson, Research. She has consulted to academia and industry on assay development, drug discovery and cancer resistance mechanisms. At the UTS School of Pharmacy she specialises in the role and regulation of the xenobiotic cascade in drug disposition and in cancer multidrug resistance (MDR).
UTSPEAKS: is a free public lecture series presented by UTS experts discussing a range of important issues confronting contemporary Australia.
Use the hashtag #utspeaks to tweet about the lecture on Twitter.
Recently, the results of the secondary analysis of VITAL research data were published in JAMA Network Open, a subsidiary of the Journal of the American Medical Association. Data shows that taking vitamin D is associated with a lower overall risk of developing advanced (metastatic or fatal) cancer, and weight can affect the association between them.
UTSpeaks: A medicated nation
Has Australia lost its way in a pharmaceutical love affair?
Professor Charlie Benrimoj and Associate Professor Mary Bebawy from the University of Technology, Sydney present at this public lecture on prescription medication held on 13 September, 2011.
How many pills will you take today? Do you really need them? What good (and bad) will they do you?
For many of us prescription medications mean the difference between good and ill-health. There’s no denying their important place in fostering well-being for many. But is it time to reflect on the complex forces at work when managing disease and medications and how this impacts you the consumer?
Featuring leading UTS researchers in pharmacy and using example case studies, this public lecture takes a critical look at how medications are prescribed and consumed in Australia. It considers whether we are getting value for money, the ideal health outcomes we hope for and whether new approaches to the responsible use and explanation of medications could be adopted.
Speakers:
Professor Shalom (Charlie) Benrimoj
Charlie Benrimoj is head of the newly-created UTS School of Pharmacy. Formerly he was Foundation Professor of Pharmacy Practice then Dean of the Faculty of Pharmacy and then Pro-Vice Chancellor (Strategic Planning) at the University of Sydney. He is a visiting professor at the University of Granada with research interests in the future of community pharmacy. He is widely published - co-authoring Community Pharmacy: Strategic Change Management in 2007. He was Australian Pharmacist of the Year in 2000 and received the Andre Bedat award in 2010 from the International Pharmacy Federation.
Associate Professor Mary Bebawy
Mary Bebawy has spent more than 14 years in research and teaching positions in academia and two years in industry as a post doctoral preclinical drug development scientist with Johnson and Johnson, Research. She has consulted to academia and industry on assay development, drug discovery and cancer resistance mechanisms. At the UTS School of Pharmacy she specialises in the role and regulation of the xenobiotic cascade in drug disposition and in cancer multidrug resistance (MDR).
UTSPEAKS: is a free public lecture series presented by UTS experts discussing a range of important issues confronting contemporary Australia.
Use the hashtag #utspeaks to tweet about the lecture on Twitter.
What went wrong with publishing in COVID19Coda Change
What went wrong with publishing in COVID19.
Naomi Hammond walks us through the good, the bad and the ugly aspects of COVID19 publications.
The ability for researchers to rapidly design and conduct trials in the midst of a pandemic was valuable.
With that however, came an 'infodemic' where consumers struggled to keep up with the abundance of information.
In April 2020, there were 6,000 articles published in one month.
This caused concerns regarding the quality of publications, the increase in opinion articles and the number of articles which were retracted over the course of Covid.
Tune in to a fascinating talk about what went wrong with publishing in COVID19.
Targeted Therapies Offer a New Approach to Cancer Treatment Natasha Tiffany
Experienced Oregon-based physician Natasha Tiffany, MD, has treated patients as a partner in Hematology Oncology of Salem since 2005. A skilled medical practitioner, Natasha Tiffany, MD, has experience administering targeted therapies in the treatment of cancer.
What is personalized medicine?
Why we need personalized medicine?
What’s Pharmacogenetics?
DNA polymorphism
Biomarkers
Today’s treatments with PM
Future insights
Challenges
What we still need to know more
Drug abuse has now become a major public health problem in Nigeria requiring urgent attention. Although drug abuse cut across all age groups, the youths are however the most affected. This study aimed at assessing Community Pharmacists involvement in the rehabilitation of drug abuse victims. The study was carried out in Abuja Municipal Area Council, questionnaires were administered to Community Pharmacists practicing within the Area Council. A total of 176 Community Pharmacists participated in the study, and slightly above a quarter (27.43%) of them had post-graduate degrees. More than three-quarters (79.5%) of the study participants had received training on drug abuse. A total of 89.2% of the study participants had come across persons suspected to be abusing prescription medicines. Almost all (96.6%) of the study participants indicated that they are willing to advise persons suspected to be abusing drugs on the dangers of drug abuse, and 88.1% of the study participants had spoken to clients concerning abuse of prescription medicines. Also, more than three-quarters (80.1%) of the study participants indicated that pharmacists’ role in the prevention of drug abuse is very important. The study has revealed that Community Pharmacists can play an invaluable role in the rehabilitation of drug abuse victims in Nigeria.
Dilbert blues almost over as companies warm up big to outsourced functionsMyCFO Services
Worried that your assistant picks up the bag the minute the clock strikes five pm and you can do nothing about it? Or that your finance department is under enormous stress when D days like September 30 (income tax filing for corporates) or March 31 are round the corner? Worse still, your Diwali shopping festival logos are still incomplete?
What went wrong with publishing in COVID19Coda Change
What went wrong with publishing in COVID19.
Naomi Hammond walks us through the good, the bad and the ugly aspects of COVID19 publications.
The ability for researchers to rapidly design and conduct trials in the midst of a pandemic was valuable.
With that however, came an 'infodemic' where consumers struggled to keep up with the abundance of information.
In April 2020, there were 6,000 articles published in one month.
This caused concerns regarding the quality of publications, the increase in opinion articles and the number of articles which were retracted over the course of Covid.
Tune in to a fascinating talk about what went wrong with publishing in COVID19.
Targeted Therapies Offer a New Approach to Cancer Treatment Natasha Tiffany
Experienced Oregon-based physician Natasha Tiffany, MD, has treated patients as a partner in Hematology Oncology of Salem since 2005. A skilled medical practitioner, Natasha Tiffany, MD, has experience administering targeted therapies in the treatment of cancer.
What is personalized medicine?
Why we need personalized medicine?
What’s Pharmacogenetics?
DNA polymorphism
Biomarkers
Today’s treatments with PM
Future insights
Challenges
What we still need to know more
Drug abuse has now become a major public health problem in Nigeria requiring urgent attention. Although drug abuse cut across all age groups, the youths are however the most affected. This study aimed at assessing Community Pharmacists involvement in the rehabilitation of drug abuse victims. The study was carried out in Abuja Municipal Area Council, questionnaires were administered to Community Pharmacists practicing within the Area Council. A total of 176 Community Pharmacists participated in the study, and slightly above a quarter (27.43%) of them had post-graduate degrees. More than three-quarters (79.5%) of the study participants had received training on drug abuse. A total of 89.2% of the study participants had come across persons suspected to be abusing prescription medicines. Almost all (96.6%) of the study participants indicated that they are willing to advise persons suspected to be abusing drugs on the dangers of drug abuse, and 88.1% of the study participants had spoken to clients concerning abuse of prescription medicines. Also, more than three-quarters (80.1%) of the study participants indicated that pharmacists’ role in the prevention of drug abuse is very important. The study has revealed that Community Pharmacists can play an invaluable role in the rehabilitation of drug abuse victims in Nigeria.
Dilbert blues almost over as companies warm up big to outsourced functionsMyCFO Services
Worried that your assistant picks up the bag the minute the clock strikes five pm and you can do nothing about it? Or that your finance department is under enormous stress when D days like September 30 (income tax filing for corporates) or March 31 are round the corner? Worse still, your Diwali shopping festival logos are still incomplete?
Distribusi Poisson adalah distribusi yang ditemukan oleh matematikawan asal Perancis
yang bernama Simeon Dennis Poisson (1781-1849). Merupakan suatu distribusi teoritis yang
memakai var random diskrit, yaitu banyaknya hasil percobaan yang terjadi dalam suatu
interval waktu tertentu.
A study on prescription pattern and rational use of statins in tertiary care ...SriramNagarajan16
Objectives
Our objectives are to evaluate prescription pattern and rational use of statins in a tertiary care corporate hospital.
Methodology
It was a prospective observational study conducted for a period of 6 months and included various departments of 300
bedded multi specialty tertiary care corporate hospital. A total of 200 patients were included and the study criteria
was inpatients and induvial more than 18 years of either gender who are prescribed with HMG-CoA reductase
inhibitors.
Results
In the present study 200 patients belonged to the age group of above 18 years, out of which about 65% were male
and 35% were female. Atorvastatin (67%) was prescribed mostly and Rosuvastatin (29.5%) was also used.
Conclusion
It is finally concluded that Rational and prophylactic use of statins can reduce further complications of Diabetes
Mellitus (DM) and cardiac events.
Statins treatment is favourable in long term treatment of diseases, it is most effectively used in treatment of serious
disease conditions which has shown its immense therapeutic role in treatment
study of compliance of diabetic patients to prescribed mediationTehreemRashid
This research comprises of data which depicts the prevalence of adherence to medication by diabetic patients and different factors that affect their compliance
Marie Germain With the elderly population living longe.docxalfredacavx97
Marie Germain
With the elderly population living longer, the rise of polypharmacy is becoming more common. Polypharmacy, the state of being in more than 5 medications causes high risk in the health of the patient and consequently becomes a huge concern for medical practitioners (Golchin, Frank, Vince, Isham & Meropol, 2015). Polypharmacy is common among the elderly people especially because of high morbidity factors. As a result, it becomes medically necessary to be on multiple medications, although it is not advisable especially given the high risk the patient is put into. The question becomes does the benefits outweigh the consequences? It is important to understand these risks and possible interventions to prevent, treat and respond to polypharmacy risks in order to improve patient outcomes.
Among the risk associated with polypharmacy are reactions between drug to drug reactions and increased risk of morbidity. Approximately 40% of the older adults are on multiple prescription drugs, while half of these are at a high risk of experiencing the risks associated with polypharmacy (Rossi, Feske, Shaffer & Kreutzer, 2017). Reaction to drugs can cause effects such as allergic reactions and other serious adverse effects that can be fatal (Azhagesan, 2017). Also, drugs may react with each other resulting in one having a greater effect than the other, and possibly hindering it from the intended action. Morbidity is the ultimate and most unprecedented risk as death may occur on the patient following immunity weakening.
As a health concern, practitioners need to respond to this issue. The first response is to examine the patient’s accurate medical history upon any given discharge. This is important in examining previous medications and how they fared well with the particular patient. This also helps to inspire the most accurate medication (Rossi, Feske, Shaffer & Kreutzer, 2017). Secondly, the medical practitioners need to reconcile medications given to the patient (Azhagesan, 2017). This helps to prevent the risk of drug to drug interactions, while adhering to early intervention to help to prevent or deal with medical issues.
Maritza Cosme
Risk Factors for Polypharmacy
Polypharmacy entails taking of 5 or more medicines. Generally, polypharmacy in the elderly occurs because of three factors: demographic factors, health factors, and access to healthcare. It is more common among older patients and has potential harms such as drug interactions and drug toxicity. Polypharmacy is an area of concern for elderly because of several reasons. Elderly people are at a greater risk for adverse drug reactions (ADRs) because of the metabolic changes and reduced drug clearance associated with ageing; this risk is furthermore exacerbated by increasing the number of drugs used. Polypharmacy is linked to increased risk of adverse drug events in older people due to increased risk of drug interactions, lack of adhe.
PHARMACOLOGICAL TREATMENT Samantha M. TallarineCapella Univ.docxkarlhennesey
PHARMACOLOGICAL TREATMENT
Samantha M. Tallarine
Capella University
BSN-FP4016
1
AGENDA
The presentation covers:
Identification of the disease
Identification of three most commonly used drugs
Types of actions, side effects and indications of the medications
Description of the treatment regime
Impact of the treatment regime on patients
How nurses should monitor clients and
Controversies associated with the medication
The presentation will focus on the issues identified. Addressing the issues provides an opportunity to identify and evaluate the selected disease in order to understand the issues affecting the patients, healthcare professional and the healthcare industry as a whole.
2
IDENTIFICATION OF THE DESEASE
The identified disease is:
Type 2 Diabetes
It’s a health condition that affects:
The body’s ability to process sugar
Mostly common for nurses among
High risk population such as those who are obese or overweight
The disease identified for the assignment is Type 2 diabetes. The disease is a health condition resulting from the inability of the body to process sugar. Even though screening is recommended for those who are 45 years and older, those who are under the age of 45 and are overweight are recommended to go for screening to determine if one is exposed to the condition and if so, the type of the condition, whether type 1 or type 2, (Fuchsberger et al., 2016).
Image sourced from: https://www.medicalnewstoday.com/articles/317769.php
3
DRUGS MOST OFTEN USED
Metformin (Glumetza , Glucophage, among others)
Generally the first prescription for the condition
Sulfonylureas
Helps the body to produce more insulin
Meglitinides
Stimulates the pancreas to produce more insulin
Metformin works by lowering the production of glucose in the liver thus improving the sensitivity of the body to insulin which improves its efficient use in the body. Sulfonylureas work by helping the body to produce more insulin thus meeting the body needs efficiently. Meglitinides also work by stimulating the production of insulin from the pancreas thus meeting the deficit by the body.
4
TYPES OF ACTIONS, SIDE EFFECTS, INDICATIONS, AND CONTRAINDICATIONS
Metformin (Glumetza , Glucophage, among others)
Possible side effects include:
Nausea and diarrhea
Sulfonylureas
Possible side effects include:
Low blood sugar and
Weight gain
The side effects of Metformin include nausea and diarrhea. The side effects disappear after the body of the patient gets used to the medication or when the medication is taken alongside a meal. Other oral medications can also be administered alongside the drug to promote positive outcomes as argued by Borries et al. (2019). The side effects of Sulfonylureas include experiences low blood sugar among the patients using the medication.
5
CONTINUATION…
Meglitinides
Faster acting medication
Thus shorted duration and effect on the body
Side effects include:
Low blood pressure and
Weight gain
The drug ...
Microalbuminuria in Saudi Adults with Type 1 Diabetes Mellitus_Crimson Publis...CrimsonPublishersIOD
Background: Diabetes mellitus is among the most common chronic non-communicable diseases. The development of microalbuminuria in type 1 diabetes increases the risk for renal and cardiovascular disease.
Methods: A cross sectional study was conducted at the Primary Health Care Clinics at King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia. A total of 334 Saudi with type 1 diabetes were randomly selected.
Results: Total of 334 patients with T2DM included in this study; 102 (30.5%) male and 232 (69.5%) female with mean age 25.8±3.4. MA was present in 99 (29.6%). MA was not significantly more prevalent in female (69.4%) with female predominance (sex ratio male: female) 1:2.3. HTN with MA was significantly more prevalent in 51(51.5%) of MA group with odd ratio 1.7 (1.2-2.4), p=0.001 with no siginificant difference between both gender. Patients with MA have significant higher HbA1c than patients with normal buminuria and there was a significant difference between gender (p< 0.0001) and when compared to HbA1c groups (p=0.002).
Conclusion: The frequency of microalbuminuria in patients with type 1 diabetes in this study is high. It is mandatory to have adequate diagnostic, therapeutic and educational resources in addition to competent physicians who can manage microalbuminuria in diabetic patients by using a continuing, comprehensive and coordinated approach.
Diabetes drug metformin may prevent dementiaDoriaFang
In addition to the role of classic hypoglycemic drugs, how many potential health benefits does metformin have? Recently, Diabetes Care, a journal of the American Diabetes Association (ADA), published a study from Australia, found that patients with type 2 diabetes who took metformin had slower cognitive decline and a lower risk of dementia.
Similar to Metformin Underused in Patients With Prediabetes (20)
1. Metformin Underused in Patients With Prediabetes
Metformin was prescribed for only 3.7% of patients with prediabetes, even though it can help
prevent the onset of type 2 diabetes, according to a new retrospective cohort analysis.
"We were surprised to see just how low the [prescription] rates were, particularly among the
highest-risk individuals, where evidence for metformin use is strongest," lead author Tannaz Moin,
MD, from the David Geffen School of Medicine at University of California, Los Angeles, told
Medscape Medical News.
"Despite inclusion in national guidelines for more than 6 years and proven long-term tolerability,
safety, and cost-effectiveness, the prescription of metformin in the real-world clinical approach to
diabetes prevention remains unclear," Dr Moin and colleagues write.
They report their findings in the April 21 issue of the Annals of Internal Medicine .
Very Little Attention Paid to Use of Metformin for Diabetes Prevention
About one in three Americans has prediabetes, which occurs when the blood glucose is higher than
normal but not high enough to be considered full-blown type 2 diabetes.
"Both metformin and lifestyle interventions have been shown to reduce risk of progression to
diabetes," Dr Moin explained.
The latest data from the ongoing US Diabetes Prevention Program (DPP), reported last summer,
showed that randomizing overweight or obese people at high risk for type 2 diabetes to intensive
lifestyle change or giving them metformin could reduce or delay the development of the disease, for
as long as 15 years in some cases.
And while it would be ideal for everyone at risk for diabetes to participate in lifestyle interventions,
efforts to translate these into practice have led to variable levels of uptake, Dr Moin said.
Meanwhile, "very little attention has been focused on the translation of evidence to support
metformin use for diabetes prevention," she noted.
In 2008, the American Diabetes Association (ADA) updated its "Standards for Medical Care in
Diabetes" guidelines to include metformin use in patients aged less than 60 years who are at very
high risk [of diabetes], are very obese (body mass index [BMI] 35 kg/m2), or have a history of
gestational diabetes.
The guidelines also say clinicians can consider metformin in those with impaired glucose tolerance,
impaired fasting glucose, or an HbA1c of 5.7% to 6.4%.
In their study, Dr Moin and colleagues analyzed data from a national sample of 17,352 adults aged
19 to 58 years with prediabetes between 2010 and 2012 who were insured for 3 continuous years to
determine the percentage who were prescribed metformin.
Over 3 years, metformin was prescribed for only 3.7% (n = 647) of patients with prediabetes.
2. Among those with a BMI 35 kg/m2 (n= 391) or gestational diabetes (n = 121) the prevalence of
metformin prescription was 7.8%. This is "the group for which the ADA guideline places the most
emphasis on treating prediabetes with metformin," the authors write.
However, this still means that fewer than one in 12 of these high-risk patients, specifically identified
by national guidelines, received metformin, they note.
After they adjusted for age, income, and education, the predicted probability of receiving a
metformin prescription was almost twice as high among women (4.8%) as it was among men (2.8%)
(P .001) and among obese participants (6.6%) compared with nonobese participants (3.5%) (P .001).
And the predicted probability of receiving a metformin prescription was 1.5 times higher among
those with two or more comorbid conditions (4.2%) compared with patients with no comorbidities
(2.8%) (P = .001).
"Metformin has long-term safety data and is readily
accessible under most prescription drug plans. Thus, it is a
tangible option to engage in diabetes prevention,
particularly among individuals at highest risk (those less
than 60 years of age, with BMI 35 kg/m2 or women with
history of gestational diabetes)," Dr Moin told Medscape
Medical News.
Physicians and Patients Should Be Educated About Metformin
"Our findings highlight a real opportunity to enhance the translation of existing evidence
surrounding diabetes prevention for large segments of the US population with prediabetes," Dr Moin
explained.
"Patients with prediabetes should be educated about all evidence-based treatment options for
diabetes prevention and their relative risks vs benefits in order to make the treatment decision that
best aligns with their preferences and levels of risk," she added.
"Metformin represents an ideal opportunity to critically examine these issues, and we hope this
study can bring the importance of this to light," she said.
She and her colleagues add that the reasons for low metformin use are not entirely clear, "and
future studies should examine an array of patient-, provider-, and organization-level factors that may
contribute to underuse.
"For providers, barriers may include lack of knowledge about the DPP or related evidence. Even
when the randomized clinical-trial evidence is fully realized, there is little guidance for the
application of these findings in real-world settings," they observe.
Also, metformin is not approved by the US Food and Drug Administration (FDA) for prediabetes,
which may increase hesitancy to prescribe it "off label" in this context, they add.
Dr Moin said the FDA is unlikely to approve metformin for the indication of prediabetes because it is
available generically and it may be too costly for the holder of the original new drug application
3. (NDA) to file a supplemental NDA for the new indication of prediabetes. Only the holders of the
original NDA can file for approval for new indications, she explained.
The study was primarily funded by Centers for Disease Control and Prevention (CDC), division of
diabetes translation, and the National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK). Dr Moin reports grants from the National Institutes of Health/NIDDK/CDC and from the
Veterans Affairs Office of Academic Affiliation/Health Services Research and Development during
the conduct of the study. Disclosures for the coauthors are listed in the article.
Ann Intern Med. 2015;162:542-548. Abstract
http://www.medscape.com/viewarticle/844072